Decisions about add-on reimbursement for medical devices in France in November 2018

19

Dec 2018

The French National Authority for Health (HAS) released new decisions about add-on and medical aid reimbursement of many medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in November 2018. The decisions were brought for twenty-two (22) medical devices.

Nine (9) decisions were released regarding prostheses:

  • GYRACUP E - GYRACUP E ULTIMATE (without cement) / SYMBOL CUP DM HA - SYMBOL CUP DMR HA (without cement) / DS EVOLUTION DM HA - DS EVOLUTION DMR HA (without cement), double mobility cups consisting of an uncemented cupule combined with a conventional polyethylene insert (application for registration, approved)
  • TREGOR MEDIAL CUP, dual mobility cup with a cemented cup and a conventional polyethylene insert (application for registration, approved)
  • NOVAE TH & COPTOS TH (without cement), dual mobility cup with a cemented cup and a conventional polyethylene insert (application for registration, rejected because the available data do not establish the interest of NOVAE TH and COPTOS TH (without cement) in reconstruction with advanced bone destruction)
  • SYMBOL CUP DM CEM (to cement) / GYRACUP E CEM (to cement) / DS EVOLUTION DM CEM (to cement), dual mobility cup with a cemented cup and a conventional polyethylene insert (application for registration, approved)
  • PROFEMUR GLADIATOR (without cement), femoral stem with the modular neck (application for registration, accepted)
  • PROFEMUR GLADIATOR (to be cemented), femoral stem with the modular neck (application for registration, accepted)
  • PROFEMUR L, femoral stem with the modular neck (application for registration, accepted)
  • CERAVER OSTEAL, centromedullary cement plug (cancelled)
  • TMJ Prostheses, total prosthesis of the temporomandibular joint (renewal of registration, approved)

Five (5) decisions were released regarding cardiovascular devices:

  • SYNERGY, a coronary stent coated with sirolimus (pharmacologically active product) (application for registration, approved)
  • ULTIMASTER TANSEI, a coronary stent coated with sirolimus (pharmacologically active product) (application for registration, approved)
  • PROMUS ELITE, a coronary stent coated with sirolimus (pharmacologically active product) (application for registration, approved)
  • PROMUS PREMIER, a coronary stent coated with sirolimus (pharmacologically active product) (application for registration, approved)
  • ACURATE NEO, transfemoral implanted aortic valve bioprosthesis (application for registration, approved)

Eight (8) decisions were released regarding other devices:

  • SPIROTEL V2, portable electronic spirometer (renewal of registration, approved)
  • ALOVA, memory foam mattress with shape memory (application for the amendment of the registration conditions, approved)
  • SILK +, intracranial stent self-expanding controlled release (stent flow diverter), (application for registration, rejected because available data did not establish the interest of SILK + in the reasons claimed)
  • HOT AXIOS, luminal biliopancreatic apposition implant and its delivery system with an electrocautery function system (application for the amendment of the registration conditions, approved)
  • ARTISAN MRI for medullary neurostimulator of the PRECISION range, decahexapolar electrode for implantable medullary neurostimulation system (application for the amendment of the registration conditions, approved)
  • LUTONIX 035 (model 9004), the paclitaxel-eluting balloon (application for registration, rejected because available data were insufficient to demonstrate the benefit of the paclitaxel-eluting balloon in patients with native arteriovenous fistula stenosis or restenosis up to 10 cm in length and 4 mm to 12 mm in diameter)
  • CICA-CARE self-adhering silicone gel plate (application for registration, approved)
  • INTELLIS, implantable and rechargeable medullary neurostimulator (application for registration, approved)

See the list of decisions in French here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more